Dimerix Enrolls First Kidney Patient to Open Label Extension Study; Shares Fall 6%
Dimerix (ASX:DXB) enrolled the first patient to an open-label extension study for its kidney disease medication DMX-200, according to a Tuesday filing with the Australian bourse.
The patient completed the pharmaceutical firm's phase three trial investigating the use of DMX-200 to treat focal segmental glomerulosclerosis, a condition that may lead to kidney scarring, the filing added.
The patient will now continue their treatment for up to two years as part of the open-label study, the filing stated.
Dimerix's shares fell 6% in recent trade.
Price (AUD): $0.38, Change: $-0.025, Percent Change: -6.17%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.